-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Opthea (NASDAQ:OPT) Shares Up 3.4%
Opthea (NASDAQ:OPT) Shares Up 3.4%
Opthea Limited (NASDAQ:OPT – Get Rating)'s stock price shot up 3.4% during trading on Tuesday . The company traded as high as $7.00 and last traded at $7.00. 691 shares traded hands during trading, a decline of 44% from the average session volume of 1,225 shares. The stock had previously closed at $6.77.
Analyst Upgrades and Downgrades
A number of research firms recently commented on OPT. SVB Leerink began coverage on shares of Opthea in a research report on Tuesday, April 26th. They set an "outperform" rating and a $25.00 price target on the stock. Truist Financial lowered their price target on shares of Opthea from $25.00 to $13.00 in a research report on Wednesday, April 13th.
Get Opthea alerts:Opthea Stock Up 3.4 %
The firm's fifty day simple moving average is $6.50 and its 200 day simple moving average is $6.28.
Hedge Funds Weigh In On Opthea
An institutional investor recently raised its position in Opthea stock. Victory Capital Management Inc. grew its stake in Opthea Limited (NASDAQ:OPT – Get Rating) by 1.4% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,596,207 shares of the company's stock after purchasing an additional 21,513 shares during the period. Victory Capital Management Inc. owned about 3.63% of Opthea worth $9,817,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 12.83% of the company's stock.Opthea Company Profile
(Get Rating)
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.
Featured Articles
- Get a free copy of the StockNews.com research report on Opthea (OPT)
- 3 Health Care Stocks in Great Financial Health
- Amazon Names Itself A Top Stock Of Q3 Contender
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Market Fundamentals Drive Results For The Williams Companies
- Pinterest Shares Are Soaring After Earnings, Is The Stock A Buy?
Receive News & Ratings for Opthea Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opthea and related companies with MarketBeat.com's FREE daily email newsletter.
Opthea Limited (NASDAQ:OPT – Get Rating)'s stock price shot up 3.4% during trading on Tuesday . The company traded as high as $7.00 and last traded at $7.00. 691 shares traded hands during trading, a decline of 44% from the average session volume of 1,225 shares. The stock had previously closed at $6.77.
在周二的交易中，Opthea Limited(纳斯达克代码：OPT-GET Rating)的股价飙升3.4%。该公司股价一度涨至7.00美元，最新报7.00美元。691股股票在交易中易手，较1,225股的平均成交量下跌44%。该股此前收盘报6.77美元。
Analyst Upgrades and Downgrades
分析师升级和下调评级
A number of research firms recently commented on OPT. SVB Leerink began coverage on shares of Opthea in a research report on Tuesday, April 26th. They set an "outperform" rating and a $25.00 price target on the stock. Truist Financial lowered their price target on shares of Opthea from $25.00 to $13.00 in a research report on Wednesday, April 13th.
一些研究公司最近对OPT发表了评论。SVB Leerink在4月26日星期二的一份研究报告中开始报道Opthea的股票。他们为该股设定了“跑赢大盘”的评级和25.00美元的目标价。在4月13日星期三的一份研究报告中，Truist Financial将Opthea的股票目标价从25.00美元下调至13.00美元。
Opthea Stock Up 3.4 %
Opthea股价上涨3.4%
The firm's fifty day simple moving average is $6.50 and its 200 day simple moving average is $6.28.
该公司的50日简单移动均线为6.50美元，200日简单移动均线为6.28美元。
Hedge Funds Weigh In On Opthea
对冲基金对Opthea的看法
Opthea Company Profile
Opthea公司简介
(Get Rating)
(获取评级)
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.
Opthea有限公司是一家临床阶段的生物制药公司，主要在澳大利亚开发和销售治疗眼病的药物。该公司的开发活动基于知识产权组合，包括用于治疗与血管和淋巴管生长以及血管渗漏相关的疾病的血管内皮细胞生长因子(VEGFC)、VEGFD和VEGFR3。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on Opthea (OPT)
- 3 Health Care Stocks in Great Financial Health
- Amazon Names Itself A Top Stock Of Q3 Contender
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Market Fundamentals Drive Results For The Williams Companies
- Pinterest Shares Are Soaring After Earnings, Is The Stock A Buy?
- 免费获取StockNews.com关于Opthea的研究报告(OPT)
- 大财务健康中的3只医疗保健类股
- 亚马逊称自己是第三季度竞争者的首选股票
- 万亿美元市值的意义不仅仅是数字
- 市场基本面推动威廉姆斯公司的业绩
- Pinterest股价在盈利后飙升，A股买入吗？
Receive News & Ratings for Opthea Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opthea and related companies with MarketBeat.com's FREE daily email newsletter.
接受Opthea Daily的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Opthea和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧